Insulin Analog, Aspart Mixed

How Does NovoLog Mix 70/30 Work?

NovoLog Mix 70/30 works through two distinct insulin components acting at different speeds. The 30% rapid-acting insulin aspart begins lowering blood glucose within 10-20 minutes of injection, reaching peak activity around 1-4 hours. It handles the blood sugar spike that occurs when you eat. The 70% intermediate-acting insulin aspart protamine dissolves slowly from the injection site, providing gradual insulin release over hours to cover background blood sugar levels between meals.

At the cellular level, insulin aspart binds to insulin receptors on muscle and fat cells. This activates glucose transporters (GLUT4) that move glucose from the bloodstream into cells, lowers hepatic glucose production, and promotes glycogen storage in the liver. Insulin aspart is a human insulin analog — nearly identical to natural human insulin but with a single amino acid change (proline replaced by aspartic acid at position B28) that causes it to be absorbed faster than regular insulin.

The protamine component provides the intermediate-acting tail: protamine is a protein that causes insulin aspart to crystallize, slowing its absorption from the subcutaneous injection site. These crystals dissolve gradually, releasing insulin aspart into the circulation over several hours — providing the basal insulin coverage that keeps blood glucose from rising between meals and overnight.

How Hard Is It to Find NovoLog Mix 70/30 in Stock?

Finding NovoLog Mix 70/30 has become significantly more challenging since 2024. The ASHP (American Society of Health-System Pharmacists) added insulin aspart protamine and insulin aspart mix to its active drug shortage list in July 2024, following Novo Nordisk's report of manufacturing delays. The situation worsened when Novo Nordisk discontinued its unbranded (generic-equivalent) versions effective December 31, 2025, narrowing supply to branded products only.

The branded NovoLog Mix 70/30 FlexPen continues to be manufactured, but availability at individual pharmacy locations is inconsistent. Large chain pharmacies — CVS, Walgreens, Rite Aid — are most likely to experience stockouts. Independent pharmacies and specialty diabetes pharmacies tend to maintain better supply. Stock varies significantly by region and by day, making it unpredictable.

If you're struggling to find NovoLog Mix 70/30 at your pharmacy, medfinder can help. medfinder is a paid service that contacts pharmacies near you to check which ones can fill your prescription — and texts you the results. Don't spend hours calling pharmacies one by one.

Who Can Prescribe NovoLog Mix 70/30?

NovoLog Mix 70/30 is not a controlled substance and has no DEA scheduling restrictions. Any licensed prescriber with authority to write prescriptions can prescribe it, provided they have a valid prescriber-patient relationship. This makes it accessible across a wide range of healthcare settings.

Providers who commonly prescribe NovoLog Mix 70/30 include:

• Endocrinologists — diabetes and hormone specialists; most commonly prescribe for type 1 diabetes or complex type 2 cases
• Primary Care Physicians (PCPs) — family medicine and internal medicine physicians routinely initiate insulin therapy in type 2 diabetes
• Nurse Practitioners (NPs) — full prescribing authority in most states for non-controlled substances including insulin
• Physician Assistants (PAs) — prescribing authority under physician supervision; commonly prescribe diabetes medications

NovoLog Mix 70/30 can be prescribed and refilled via telehealth in all 50 states, as it is not a controlled substance. Telemedicine services including Teladoc, MDLive, and Amazon Clinic can evaluate and prescribe for patients with established diabetes diagnoses. This is particularly useful for patients in rural areas with limited access to endocrinologists or for patients who need bridge prescriptions between in-person visits.

Is NovoLog Mix 70/30 a Controlled Substance?

No. NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart) is not a controlled substance and is not scheduled by the DEA. There are no federal DEA restrictions on prescribing it, and it can be prescribed by any licensed healthcare provider including physicians, nurse practitioners, and physician assistants without special DEA authorization.

Because it is not a controlled substance, NovoLog Mix 70/30 can be prescribed and refilled without special controls, e-prescribing requirements, or quantity limits imposed by the DEA. It can also be prescribed via telehealth in all 50 states. State-level regulations may vary, but there are no federal restrictions beyond a valid prescription requirement.

Common Side Effects of NovoLog Mix 70/30

The most common side effects reported with NovoLog Mix 70/30 include:

• Hypoglycemia (low blood sugar) — the most frequent adverse reaction with all insulin therapy; symptoms include shakiness, sweating, confusion, and rapid heartbeat
• Injection site reactions — redness, swelling, itching, or pain at the injection site
• Lipodystrophy — skin thickening (lipohypertrophy) or pitting (lipoatrophy) from repeated injections in the same area
• Weight gain — due to anabolic effects of insulin and improved glycemic control
• Peripheral edema — mild fluid retention, especially when starting insulin therapy
• Rash and pruritus — occurred in approximately 7% of patients in clinical trials

Serious side effects requiring immediate medical attention:

• Severe hypoglycemia — unconsciousness, seizures, potential permanent brain damage or death if untreated
• Anaphylaxis — severe generalized allergic reaction including difficulty breathing, swelling of the tongue or throat, rapid pulse
• Hypokalemia — dangerously low potassium levels that can cause respiratory paralysis or fatal cardiac arrhythmias
• Heart failure (with thiazolidinediones) — fluid retention risk when combined with pioglitazone or rosiglitazone

Final Thoughts on NovoLog Mix 70/30

NovoLog Mix 70/30 remains a valuable option for adults with type 1 and type 2 diabetes who benefit from the convenience of a premixed, twice-daily insulin regimen. Its rapid onset allows flexible mealtime dosing within 15 minutes of eating, a significant clinical advantage over older human premixed insulins that require 30-45 minute pre-meal injection. The ongoing shortage and discontinuation of unbranded versions have made it harder to find, but the branded FlexPen continues to be manufactured.

With Novo Nordisk's significant price reductions effective January 2026, the out-of-pocket cost has dropped dramatically. Multiple savings programs — including the $35/month savings card for commercially insured patients, My Insulin Rx for uninsured patients, and the Novo Nordisk Patient Assistance Program for eligible low-income patients — mean there is a path to affordability for nearly every patient situation.

If your primary challenge is locating NovoLog Mix 70/30 in stock rather than affording it, medfinder is designed to solve exactly that problem. medfinder contacts pharmacies near you to find which ones can fill your prescription, then texts you the results — saving hours of frustrating phone calls during the ongoing insulin shortage.